Next-Generation Imaging

Latest News

Approval sought for TLX007-CDx in prostate cancer
Approval sought for TLX007-CDx in prostate cancer

May 28th 2024

“If approved by the FDA, this new product will have a significant impact on prostate cancer patients, physicians, and their caregivers by helping to eliminate the inequity of access to PSMA-PET agents, and increase the ability to accurately diagnose cancer early, reducing the cost of care, and increasing the probability of patients’ survival," says Mike Crosby.

Dosing begins in study of PSMA-targeted therapy in mCRPC
Dosing begins in study of PSMA-targeted therapy in mCRPC

May 10th 2024

Multi-dose treatment with 67Cu-SAR-bisPSMA in mCRPC shows promise
Multi-dose treatment with 67Cu-SAR-bisPSMA in mCRPC shows promise

April 30th 2024

Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Licensing agreement reached for contrast agent for use in patients with prostate cancer

April 30th 2024

First patient dosed with TLX250-CDx for ccRCC in Australia
First patient dosed with TLX250-CDx for ccRCC in Australia

April 29th 2024

Video Series
Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.